Posted on

Artificial intelligence to find "elder life medicine", candidate molecules have come out

February 06, 2018 Source: WuXi PharmaTech

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

Today, Juvenescence Ltd. announced that Juvenescence.AI, a company founded in collaboration with Insilico Medicine, has selected the first group of compounds for further clinical development. Juvenescence.AI is a company focused on the use of artificial intelligence (AI) for drug development, focusing on drug development in the areas of aging and aging-related diseases. Juvenescence.AI has the right to obtain a clinical development license for a total of five compound families from Insilico under a cooperative agreement between Juvenescence Ltd and Insilico.

Juvenescence Ltd. is a company focused on developing longevity in human health. Insilico is a biotechnology company that uses AI for drug discovery and development to treat diseases related to aging. The company uses advances in genomics, big data analysis, and deep learning to guide computer-simulated drug screening processes. The company's drug development pipeline includes drug candidates for the treatment of cancer, metabolic diseases, neurodegenerative diseases, fibrotic diseases, skin diseases and other diseases. The creation of Juvenescence.AI represents the in-depth collaboration between Juvenescence's drug developers and Insilico's AI experts. It also means that the era of drug discovery has been discovered in the drug discovery process using highly complex AI. Less than six months after the start of the collaboration, the research team has discovered a molecular target for treating specific aging-related diseases. JAI-001 and its analogs developed by the joint team have shown activity in in vitro assays associated with aging diseases.

â–²Insilico Medicine's technical details (Source: Insilico Medicine official website)

"For Juvenescence, the selection of the first group of compounds is a milestone. This is also an important sign of AI's potential in the innovative drug development industry," said Jim Mellon, chairman of Juvanescence.

Dr. Greg Bailey, CEO of Juvanescence, added: "Juvenescence's drug developers are excited to work with Insilico to change the drug development model. The first group of compounds was selected to further validate Insilico's ability to discover innovative drugs using AI. ”

â–² Dr. Alex Zhavoronkov, CEO of Insilico Medicine, talks about the application of artificial intelligence in the development of new drugs at the 2018 WuXi PharmaTech Global Forum

Researchers are currently working to discover innovative molecules for other targets and verify their effects in cell culture experiments.

Reference materials:

[1] Insilico Medicine and Juvenescence Announce First Drug Candidate for Their Joint Venture Company Juvenescence.AI

[2] Juvenescence.AI official website

[3] Insilico Medicine Official Website

Disposal Medical Supply

Medical Equipment Disposal,Syringes Needles Sizes,Disposable Syringe,Insulin Syringe

FOSHAN PHARMA CO., LTD. , https://www.fspharmamedicine.com